ERBB2 and breast cancer: In the renowned NSABP B-27 trial orchestrated by the National Surgical Adjuvant Breast and Bowel Project, the potential of introducing docetaxel to a foundational regimen of AC in the neoadjuvant setting was closely examined for operable BC, inclusive of the HER2-negative subtype.50 Participants, who were subjected to varying sequences of the aforementioned drugs, presented a pCR rate of 26.1% when doxorubicin and cyclophosphamide were succeeded by docetaxel.